143 related articles for article (PubMed ID: 37892089)
1. Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission.
Hsiao SW; Chen TC; Su PY; Yang CT; Huang SP; Chen YY; Yen HH
Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892089
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
[TBL] [Abstract][Full Text] [Related]
3. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors.
Rodriguez-Duque JC; Calleja JL; Iruzubieta P; Hernández-Conde M; Rivas-Rivas C; Vera MI; Garcia MJ; Pascual M; Castro B; García-Blanco A; García-Nieto E; Olmo SC; Cagigal ML; Lopez-Montejo L; Fernández-Lamas T; Rasines L; Fortea JI; Vaque JP; Frias Y; Rivero M; Arias-Loste MT; Crespo J
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):406-414.e7. PubMed ID: 35124272
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease.
Veltkamp C; Lan S; Korompoki E; Weiss KH; Schmidt H; Seitz HK
J Clin Med; 2022 May; 11(9):. PubMed ID: 35566749
[TBL] [Abstract][Full Text] [Related]
6. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study.
Yen HH; Su PY; Huang SP; Wu L; Hsu TC; Zeng YH; Chen YY
PLoS One; 2021; 16(5):e0252286. PubMed ID: 34043691
[TBL] [Abstract][Full Text] [Related]
8. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.
Carr RM; Patel A; Bownik H; Oranu A; Kerner C; Praestgaard A; Forde KA; Reddy KR; Lichtenstein GR
Dig Dis Sci; 2017 May; 62(5):1354-1361. PubMed ID: 28265826
[TBL] [Abstract][Full Text] [Related]
9. Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease.
Liu TT; Qiu H; Liu SY; Chien C; Wang JH; Wong MW; Yi CH; Lin L; Lei WY; Liang SW; Hung JS; Huang JF; Chen CL; Han MAT
Kaohsiung J Med Sci; 2022 Oct; 38(10):1012-1019. PubMed ID: 35993503
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study.
Losurdo G; La Fortezza RF; Iannone A; Contaldo A; Barone M; Ierardi E; Di Leo A; Principi M
World J Gastroenterol; 2020 Dec; 26(47):7528-7537. PubMed ID: 33384552
[TBL] [Abstract][Full Text] [Related]
11. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
12. [Applied research of ultrasound attenuation parameter in the diagnosis of metabolic dysfunction-associated fatty liver disease].
Hou MM; Yuan XW; Wang YQ; Zhang Y; Zhang SY; Yu SH; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):290-296. PubMed ID: 35462485
[No Abstract] [Full Text] [Related]
13. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
Shang MY; Chen YZ; Bao J; Tong YL
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
[No Abstract] [Full Text] [Related]
14. Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter.
Trifan A; Stafie R; Rotaru A; Stratina E; Zenovia S; Nastasa R; Huiban L; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Sfarti C; Cojocariu C; Petrea O; Stanciu C
J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233826
[TBL] [Abstract][Full Text] [Related]
15. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population.
Yang S; Cheng J; Zhang R; Sun H; Zhang H; Lyu S; Duan W
Hepatol Res; 2022 Feb; 52(2):176-186. PubMed ID: 34751487
[TBL] [Abstract][Full Text] [Related]
16. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Hepatol Commun; 2022 Aug; 6(8):2070-2078. PubMed ID: 35470984
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.
Magrì S; Paduano D; Chicco F; Cingolani A; Farris C; Delogu G; Tumbarello F; Lai M; Melis A; Casula L; Fantini MC; Usai P
World J Gastroenterol; 2019 Oct; 25(37):5676-5686. PubMed ID: 31602167
[TBL] [Abstract][Full Text] [Related]
18. Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease.
Hyun HK; Lee HW; Park J; Park SJ; Park JJ; Kim TI; Lee JS; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU; Cheon JH
Gut Liver; 2024 Mar; 18(2):294-304. PubMed ID: 37203442
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
Sourianarayanane A; Garg G; Smith TH; Butt MI; McCullough AJ; Shen B
J Crohns Colitis; 2013 Sep; 7(8):e279-85. PubMed ID: 23158500
[TBL] [Abstract][Full Text] [Related]
20. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
Cheng YM; Hsieh TH; Wang CC; Kao JH
JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
